Lobe Sciences Ltd. Completes Private Placement Upsize

Lobe Sciences Ltd., a clinical-stage biopharmaceutical company, has successfully closed the second tranche of a non-brokered private placement of common shares. Priced at $0.085 per share, this tranche consisted of 705,882 shares, raising $60,000. This follows an initial tranche closed on August 19, 2026, with 24,705,880 shares issued for $2,100,000. In total, the company has raised $2,160,000 through this placement.

The proceeds will support working capital and general corporate purposes. Additionally, funds will be allocated to advancing the S-100 drug candidate for sickle cell disease treatment, particularly through its subsidiary, Applied Lipid Technologies, Inc. The active pharmaceutical ingredient necessary for human clinical trials has been secured, facilitating progression.

Securities issued during this placement are subject to a four-month hold period in accordance with Canadian laws. These securities are not registered for sale in the United States and are restricted from being offered or sold without the necessary registration or exemption.